ArticleCancer medicine2025
HBX Multi-Mutations Combined With Traditional Screening Indicators to Establish a Nomogram Contributes to Precisely Stratify the High-Risk Population of Hepatocellular Carcinoma.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors, often diagnosed at an advanced stage with limited treatment options and a poor prognosis. The present study aimed to identify the risk factors (RFs) for HCC and develop a nomogram incorporating dominant HBX mutations to predict the risk of HCC occurrence in high-risk (HR) populations.
methodsWe collected early HCC screening and monitoring factors from cohorts of HCC patients and HR populations, including gender, age, AFP, ALT, as well as hepatitis B virus (HBV) infection and mutation indicators such as hepatitis B surface antigen (HBsAg), HBV DNA replication level, HBV genotype, and high-frequency mutations in HBX. Independent predictive factors for HCC onset were determined through both univariate and multivariate logistic regression analyses. Two nomograms with and without HBX mutation data were established to predict the risk of HCC incidence in HR populations, and their performance was evaluated using calibration curves, receiver operating characteristic (ROC) curves, as well as decision curve analysis (DCA).
resultsA total of 312 participants were included. Independent RFs for HCC onset were identified as A1762T+G1764A multi-mutations, T1753C/G/A+A1762T+G1764A multi-mutations, and ALT > 40 U/L. The area under the curve (AUC) of the diagnostic nomogram with HBX mutation data was 0.835 in the training set and 0.869 in the testing set for the nomogram. Besides, the AUC of the diagnostic nomogram without HBX mutation data in the training set was 0.798 and 0.818 in the testing set. The calibration curve together with DCA indicated that the nomogram containing HBX mutation data had better predictive performance.
conclusionsThe established nomograms predicted the risk of HCC occurrence in HR populations with good accuracy, providing a valuable reference for precise stratification of HR populations and HCC screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.